Zinman, B., Tušek, S., Mirošević, G., Goldoni, V., Jurišić Eržen, D., Balaško, A. ... Fitchett, D. (2018). Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®. Diabetologia (Berlin), 61. (7), 1522-1527. doi: 10.1007/s00125-018-4630-2
Zinman, Bernard, et al. "Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®." Diabetologia (Berlin), vol. 61, no. 7, 2018, pp. 1522-1527. https://doi.org/10.1007/s00125-018-4630-2
Zinman, Bernard, Srećko Tušek, Gorana Mirošević, Vesna Goldoni, Dubravka Jurišić Eržen, Annemarie Balaško, Stjepan Balić, Ema Drvodelić Šunić, Silvija Canecki Varžić and David Fitchett. "Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®." Diabetologia (Berlin) 61, no. 7 (2018): 1522-1527. https://doi.org/10.1007/s00125-018-4630-2
Zinman, B., et al. (2018) 'Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®', Diabetologia (Berlin), 61(7), pp. 1522-1527. doi: 10.1007/s00125-018-4630-2
Zinman B, Tušek S, Mirošević G, Goldoni V, Jurišić Eržen D, Balaško A, and sur.. Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®. Diabetologia (Berlin) [Internet]. 2018 [cited 2024 October 29];61(7):1522-1527. doi: 10.1007/s00125-018-4630-2
B. Zinman, et al., "Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®", Diabetologia (Berlin), vol. 61, no. 7, pp. 1522-1527, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:795484. [Accessed: 29 October 2024]